Summary
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
History
Renalytix AI was founded in June 2016 and launched its first product in the US in 2019. The company collaborates with leading US academic medical centers, research centers and dialysis providers.
Mission
Renalytix AI will optimize kidney care through innovations in predictive analytics, artificial intelligence and data-driven insights.
Vision
Renalytix AI’s vision is to identify, track and manage Americans at risk of kidney disease and its complications.
Key Team
Ms. Andria Parks-Herrera (VP of Marketing)
Ms. Jean M. Casner (Sr. VP & Chief HR Officer)
Dr. Michael J. Donovan M.D., Ph.D. (Chief Medical Officer)
Mr. Baljit Singh (Head of Clinical Operations)
Mr. Salim Hamir F.C.A. (Company Sec.)
Mr. Oliver James Sterling III (Chief Financial Officer)
Recognition and Awards
Renalytix has been recognized as a Top 10 AI Company in Georgia in 2020 by TNW and a Top 25 Healthcare AI Company in the US in 2019 by CIO Applications.
References
